Summit Therapeutics Inc. - COM (SMMT)

CUSIP: 86627T108

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Equity / COM
Total 13F shares
117,788,000
Share change
+14,928,945
Total reported value
$2,060,259,947
Put/Call ratio
149%
Price per share
$17.49
Number of holders
205
Value change
+$249,329,721
Number of buys
102
Number of sells
123

Quarterly Holders Quick Answers

What is CUSIP 86627T108?
CUSIP 86627T108 identifies SMMT - Summit Therapeutics Inc. - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Summit Therapeutics Inc. - COM (SMMT) as of Q4 2025

As of 31 Dec 2025, Summit Therapeutics Inc. - COM (SMMT) was held by 205 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 117,788,000 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, FMR LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, Polymer Capital Management (HK) LTD, and Pictet Asset Management Holding SA. This page lists 205 institutional shareholders reporting positions in this security for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.